Brief: ContraFect Announces Initiation Of Pivotal Phase 3 Disrupt Study Of Exebacase As A Treatment For Staph Aureus Bacteremia, Including Right-Sided Endocarditis
20/12/2019 13:08
Dec 20 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES INITIATION OF PIVOTAL PHASE 3 DISRUPT
STUDY
OF EXEBACASE AS A TREATMENT FOR STAPH AUREUS BACTEREMIA,
INCLUDING RIGHT-SIDED ENDOCARDITIS
Source text for Eikon: ID:nGNX8zkMfP
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370